http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sung Ill Jang ),( Lee Yong Paik ),( Su Yeon Lee ),( Joon Mee Kim ),( Dong Ki Lee ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: The increasing prevalence of cholesterol gallstone (CG) disease has become an economic burden to the healthcare system. Ursodeoxycholic acid (UDCA) is the only established medical agent used to dissolve gallstones. In investigating novel therapeutics for CG, we assessed the therapeutic effects of eicosapentaenoic acid (EPA), which is one of most bioactive omega-3 polyunsaturated fatty acids, on CG induced by feeding a lithogenic diet (LD) containing high cholesterol levels to mice. Methods: Mice were divided into the following four groups: (A) LD; (B) LD+EPA; (C) LD+UDCA; (D) LD+EPA+UDCA. After LD feeding for 10 weeks, EPA or UDCA was administered orally and the diet maintained for 16 weeks. The levels of phospholipids and cholesterol in bile, CG dissolution, gallbladder wall thickness, MUC gene expression ingallbladder were analyzed. Results: Mice in the EPA treatment (Groups B, D) showed signifi cantly higher stone dissolution than the control LD group (Groups A). The combination treatment of EPA and UDCA accelerate stone dissolution more than mono-therapy with EPA or UDCA. Bile phospholipid levels were signifi cantly elevated and cholesterol saturation index was decreased in the Group B. Although hypertrophy of the gallbladder wall was evident in mice fed LD, the wall thickness of gallbladder in mice treated with EPA (Group B, D) was signifi cantly thinner than in mice fed LD. MUC 2, 5ac, 5b and 6 mRNA expression levels were signifi cantly elevated in the LD-fed group, and this was suppressed by EPA with or without UDCA. Conclusions: EPA dissolves cholesterol gallstone in mouse through increasing the levels of bile phospholipids, decreasing cholesterol saturation and suppressing bile mucin formation. Further human study is required to investigate the therapeutic effects of EPA in patients with CG.
Residue of Clindamycin in the Muscles of Eel and Flounder Infected by Streptococcus sp. by HPLC
Jang, Won-Cheoul,Shim, Sang-Kyun,Heo, Gang-Joon Korean Society of ToxicologyKorea Environmental Mu 1997 Toxicological Research Vol.13 No.3
Residue and recoveries of clindamycin were investigated by reversed-phase high performance liquid chromatography (RP-HPLC) which was infected for the control of streptcoccal infection in Anguilla japonica and Paralichthys olivaceusis. Detection limit was 0.1 ppm. Recoveries of clindamycin in muscles of flounder and eel were 80.4 and 78.8%, respectively. The clindamycin in eel and flounder was detected up to 13 and 15 days after dosing, respectively.
( Sang Hoon Ahn ),( Young-Suk Lim ),( Si-Hyun Bae ),( Hyung Joon Kim ),( Kwan Sik Lee ),( Won Young Tak ),( Byoung Kuk Jang ),( Ki Tae Yoon ),( Seung Woon Paik ),( Kwan Soo Byun ),( Sunjin Hwang ),( B 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: In this Phase-3 randomized, double-blind, active-controlled study in 425 HBeAg-negative patients, the efficacy of TAF was demonstrated to be non-inferior to that of TDF at Week48 in the proportion with HBV DNA<29 IU/mL with improved bone and renal effects. Here we present the subgroup efficacy analysis of Korea patients in the study. Methods: Patients with HBeAg-negative CHB were randomized 2:1 to TAF 25mg or TDF 300mg, and treated for 96weeks. The primary efficacy analysis was the proportion with HBV DNA<29 IU/mL at Week48. The results for the subgroup of Korean patients were compared to non-Koreans. Results: Of the 425 patients who were randomized and treated, 45 subjects (11%; TAF 30; TDF 15 subjects) were enrolled in Korea. In contrast to the non-Korea population, the Korea population for the TAF and TDF groups included a higher proportion of females (60% and 47%) a lower mean baseline HBV DNA level, and more treatment experienced subjects. Nearly all were genotype C. Key efficacy end points are summarized in the Table. The percentages of Korean subjects with HBV DNA levels<29 IU/mL at Week48 were 100.0% with TAF and 80.0% with TDF. The results were consistent with the non-Korean and overall populations. A greater percentage of patients treated with TAF also achieved normalization of serum ALT values. The rates of treatment discontinuations and serious AEs were low and similar in the two arms. No viral resistance was observed overall. Similar to non-Korean subjects, those from Korea who were treated with TAF also showed smaller declines in BMD at hip and spine and in CrCl at Week48 compared with TDF subjects in Korea. Conclusions: Compared to TDF 300mg, the efficacy and safety of TAF 25mg in patients with HBeAg-negative CHB from Korea were consistent with those of the nonKorea and overall populations at Week48.
JANG, Chan Ho,LEE, In Ae,HA, Young Ran,LIM, Jinkyu,SUNG, Mi-Kyung,LEE, Sung-Joon,KIM, Jong-Sang Japan Society for Bioscience, Biotechnology, and A 2008 Bioscience, Biotechnology, and Biochemistry Vol.72 No.7
<P>Few protein biomarkers for oxidative stress have been reported. In this study, we attempted to identify the proteins selectively overexpressed in human colon tumor cells by treating with hydrogen peroxide as oxidative stress. A proteomic analysis followed by western blotting showed that phosphoglycerate kinase 1 (PGK1) was induced by hydrogen peroxide in a dose-dependent manner, while its expression was suppressed by a co-treatment with delphinidin, a known antioxidant. Furthermore, several antioxidants, including α-tocopherol, butylated hydroxytoluene (BHT), and Trolox, also inhibited the PGK1 induction caused by hydrogen peroxide. The data suggest that PGK1 might be a potential protein biomarker of intracellular oxidative status.</P>
Jang, Yu Mi,Oh, Yeon-Mok,Seo, Joon Beom,Kim, Namkug,Chae, Eun Jin,Lee, Young Kyung,Lee, Sang Do Lippincott Williams Wilkins, Inc. 2008 Vol. No.
OBJECTIVES:: The purpose of this study is to evaluate the correlation of the perfusion parameters of 3-dimensional, contrast-enhanced magnetic resonance (MR) imaging (3D CEMRI) with pulmonary function test (PFT) and quantitative computed tomography (CT) parameters in patients with chronic obstructive pulmonary disease (COPD). MATERIALS AND METHODS:: In 14 patients with COPD, 3D CEMRI was performed. From the signal intensity-time curves, pulmonary blood flow (PBF), pulmonary blood volume (PBV), and mean transit time of each pixel was calculated. From the volumetric CT data, the quantitative parameters including the volume fraction of the lung below −950 Housefield Units (V−950) and mean lung density were assessed. The correlation between the MR perfusion parameters and the parameters from quantitative CT and PFT was assessed using Spearman correlation analysis. The correspondence of the regional impairment of perfusion on MR perfusion maps to the areas of emphysema on quantitative CT maps in each patient was assessed qualitatively using a 4-class visual scoring method by 2 readers. RESULTS:: All 3D CEMRI examinations were successfully completed and MR perfusion parameters were obtained in all patients. The Spearman correlation test showed that PBF positively correlated with forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) (R = 0.49, P = 0.044), PBV positively correlated with FEV1/FVC (R = 0.69, P = 0.006) and negatively correlated with V−950 (R = −0.61, P = 0.020), and mean transit time positively correlated with FEV1 (R = 0.63, P = 0.017) and FEV1/FVC (R = 0.76, P = 0.002). The areas of perfusion impairment on PBF and PBV maps were relatively well correlated with the areas of emphysema on CT maps [very good or good: PBF 71.5% (reader 1) and 64.3% (reader 2) of the patients, &kgr; = 0.47 (P < 0.001); PBV 78.6% (reader 1) and 78.6% (reader 2) of the patients, &kgr; = 0.89 (P < 0.001)]. CONCLUSIONS:: This study shows that the deterioration of perfusion parameters measured on MR in patients with COPD, correlates with worsening of airflow limitation on PFT and emphysema index on CT. Regional heterogeneity of emphysema on CT matches with the decreased perfusion on MR.
( Sang Hoon Ahn ),( Won Kim ),( Young Kul Jung ),( Jin Mo Yang ),( Jae Young Jang ),( Yong Oh Kweon ),( Yong Kyun Cho ),( Yoon Jun Kim ),( Gun Young Hong ),( Dong Joon Kim ),( Soon Ho Um ),( Joo Hyun 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Besifovir is an acyclic nucleotide phosphonate known to be effective in hepatitis B virus (HBV) DNA suppression for both treatment- naïve and lamivudine-resistant chronic HBV infection in preliminary studies. We assessed the safety and efficacy of besifovir comparing with tenofovir in treatment-naïve chronic hepatitis B patients. Methods: A total of 187 patients were randomly received besifovir dipivoxil 150mg or tenofovir disoproxil fumarate 300mg. Eligible subjects were patients with chronic HBV infection. We measured the proportion of patients who had HBV DNA less than 69 IU/mL at week 48 as the primary efficacy endpoint. Key secondary endpoints were histological response (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis), serum HBV DNA reduction, and liver function tests. Also, bone mineral density (BMD) and renal parameters were evaluated. Results: The proportion of patients who achieved primary endpoint of HBV DNA (< 69 IU/mL) at week 48 were 85.33% and 88.75% among those who received besifovir and tenofovir, respectively. Besifovir was shown to be non-inferior to tenofovir (lower limit of 95% CI for the treatment difference =-0.14). Histological improvement of 29 patients who underwent liver biopsy was evaluated, and we found that significantly more patients treated with besifovir had improved histological response than those treated with tenofovir (77.78% vs. 36.36%, p=0.0482). There was no difference in intrahepatic cccDNA reduction between the two groups (p=0.35). None of the patients had resistant to mutations or increase in serum creatinine >0.5mg/dL from baseline. Patients who received besifovir had smaller decrease in BMD during 48 weeks than that of tenofovir (besifovir -0.02±0.44, tenofovir -0.10±0.86, p=0.0248). There was no adverse drug reaction leading the patients to withdrawal. Conclusions: This phase 3 study demonstrated that besifovir had comparable efficacy and safety profile to tenofovir in the treatment of treatment-naïve chronic hepatitis B patients. Besifovir showed better profile than tenofovir in both histological response and bone loss. An open-label extension study is ongoing with besifovir to investigate long-term efficacy and safety.
Age as a clinical predictor of relapse after induction therapy in ulcerative colitis.
Jang, Eun Sun,Lee, Dong Ho,Kim, Jaihwan,Yang, Hyo-Joon,Lee, Sang Hyub,Park, Young Soo,Hwang, Jin Hyoek,Kim, Jin-Wook,Jeong, Sook-Hyang,Kim, Nayoung,Jung, Hyun Chae,Song, In Sung G. Thieme 2009 Hepato-gastroenterology Vol.56 No.94
<P>BACKGROUND/AIMS: Whether older patients with ulcerative colitis (UC) have a better clinical course than younger patients is unclear. We compared the clinical characteristics between older and younger age groups in South Korea to elucidate the impact of age on relapse in UC. METHODOLOGY: Patients between 18 and 85 years old who were diagnosed with UC at Seoul National University Bundang Hospital between 1 May 2003 and 31 Oct 2007 were enrolled. It was reviewed their symptoms, endoscopic and pathologic findings, and drugs used in induction treatment. RESULTS: Of the 73 patients with UC who achieved remission after induction treatment, 38 relapsed. The patients aged 18-44 and 45-85 years had similar clinical features, but the relapse rate was significantly higher in the younger group (69.2 vs. 32.4%; p = 0.002). In a multivariable analysis, age 45-85 years old was an independent protective factor against relapse (OR, 0.146; 95% CI, 0.035-0.508; p = 0.003) after adjusting for sex, frequency of diarrhea, hematochezia grade, disease extent, and systemic steroid used in induction treatment. CONCLUSION: An age of 45 years or older is an independent predictor of less relapse in UC.</P>